Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

We expect disappointing results in the first quarter will be balanced by higher-than-anticipated growth in the second half.

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Mark Groves is a human connection specialist who teaches individuals and companies how to strengthen their relationships.

Novo Nordisk A/S NVO reported first-quarter 2025 earnings of 92 cents per American Depositary Receipt (ADR), which matched ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

CVS stock has an attractive yield and earnings expansion. That makes it worth a look for investors seeking growth and income.